Efficacy and Safety of Pyronaridine-Artesunate Plus Single-Dose Primaquine for the Treatment of Malaria in Western Cambodia

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2019 Jul 31

PMID 31358594

Citations 12

Authors

Rithea Leang

Nimol Khim

Huch Chea

Rekol Huy

Melissa Mairet-Khedim

Denis Mey Bouth

Maria Dorina Bustos

Pascal Ringwald

Benoit Witkowski

Affiliations

Soon will be listed here.

Abstract

This single-arm trial ( = 104) in western Cambodia showed high efficacy for 3-day treatment with pyronaridine-artesunate plus single-dose primaquine in malaria. Day 42 PCR-adjusted adequate clinical and parasitological response (ACPR) was 98.3% (58/59) (95% confidence interval [CI], 90.9 to 100.0) in Trapeng Chau in Kampong Speu and 100% (41/41) (95% CI, 91.4 to 100) in Veal Veng in Pursat; 80.6% (83/103) of the patients had with drug resistance molecular markers. For malaria, pyronaridine-artesunate day 28 ACPR was 98.3% (59/60) (95% CI, 91.1 to 100) and 100% (60/60) (95% CI, 94.0 to 100), respectively. (This study is registered in the Australian New Zealand Clinical Trials Registry [ANZCTR] under reference no. ACTRN12618001999224.).

Citing Articles

Therapeutic efficacy of pyronaridine-artesunate (Pyramax) in treating malaria in the central highlands of Vietnam.

Manh N, Thanh N, Quang H, Van N, San N, Phong N Antimicrob Agents Chemother. 2024; 68(9):e0004424.

PMID: 39046237 PMC: 11373200. DOI: 10.1128/aac.00044-24.

Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa.

Rosenthal P, Asua V, Conrad M Nat Rev Microbiol. 2024; 22(6):373-384.

PMID: 38321292 DOI: 10.1038/s41579-024-01008-2.

Efficacy and safety of pyronaridine-artesunate (Pyramax) for the treatment of uncomplicated Plasmodium vivax malaria in Northwest Ethiopia.

Mohammed H, Sime H, Hailgiorgis H, Chernet M, Alebachew M, Solomon H Malar J. 2022; 21(1):401.

PMID: 36587210 PMC: 9805271. DOI: 10.1186/s12936-022-04422-0.

Prospective observational study to evaluate the clinical and biological safety profile of pyronaridine-artesunate in a rural health district in Burkina Faso.

Rouamba T, Sondo P, Yerbanga I, Compaore A, Traore-Coulibaly M, Hien F Pharmacol Res Perspect. 2022; 10(4):e00987.

PMID: 35855566 PMC: 9297024. DOI: 10.1002/prp2.987.

Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.

Pryce J, Taylor M, Fox T, Hine P Cochrane Database Syst Rev. 2022; 6:CD006404.

PMID: 35726133 PMC: 9209011. DOI: 10.1002/14651858.CD006404.pub4.

References

Miotto O, Almagro-Garcia J, Manske M, MacInnis B, Campino S, Rockett K . Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet. 2013; 45(6):648-55. PMC: 3807790. DOI: 10.1038/ng.2624. View

Noedl H, Se Y, Schaecher K, Smith B, Socheat D, Fukuda M . Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008; 359(24):2619-20. DOI: 10.1056/NEJMc0805011. View

Denis M, Tsuyuoka R, Poravuth Y, Narann T, Seila S, Lim C . Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health. 2006; 11(9):1360-6. DOI: 10.1111/j.1365-3156.2006.01690.x. View

Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A, Khim N . A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2013; 505(7481):50-5. PMC: 5007947. DOI: 10.1038/nature12876. View

Lin J, Patel J, Levitz L, Wojnarski M, Chaorattanakawee S, Gosi P . Gametocyte Carriage, Antimalarial Use, and Drug Resistance in Cambodia, 2008-2014. Am J Trop Med Hyg. 2018; 99(5):1145-1149. PMC: 6221238. DOI: 10.4269/ajtmh.18-0509. View

Dysoley L, Kim S, Lopes S, Khim N, Bjorges S, Top S . The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians. BMC Infect Dis. 2019; 19(1):250. PMC: 6419451. DOI: 10.1186/s12879-019-3862-1. View

Rossi G, De Smet M, Khim N, Kindermans J, Menard D . Emergence of Plasmodium falciparum triple mutant in Cambodia. Lancet Infect Dis. 2017; 17(12):1233. DOI: 10.1016/S1473-3099(17)30635-7. View

Leang R, Mairet-Khedim M, Chea H, Huy R, Khim N, Mey Bouth D . Efficacy and Safety of Pyronaridine-Artesunate plus Single-Dose Primaquine for Treatment of Uncomplicated Malaria in Eastern Cambodia. Antimicrob Agents Chemother. 2019; 63(3). PMC: 6395891. DOI: 10.1128/AAC.02242-18. View

Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C . Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016; 16(3):357-65. PMC: 4792715. DOI: 10.1016/S1473-3099(15)00487-9. View

10.

Lin J, Lon C, Spring M, Sok S, Chann S, Ittiverakul M . Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open-label randomized trial. PLoS One. 2017; 12(6):e0168702. PMC: 5462369. DOI: 10.1371/journal.pone.0168702. View

11.

Witkowski B, Duru V, Khim N, Ross L, Saintpierre B, Beghain J . A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis. 2016; 17(2):174-183. PMC: 5266792. DOI: 10.1016/S1473-3099(16)30415-7. View

12.

Leang R, Canavati S, Khim N, Vestergaard L, Fuhrer I, Kim S . Efficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated Plasmodium falciparum Malaria in Western Cambodia. Antimicrob Agents Chemother. 2016; 60(7):3884-90. PMC: 4914696. DOI: 10.1128/AAC.00039-16. View

13.

Leang R, Taylor W, Mey Bouth D, Song L, Tarning J, Char M . Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment. Antimicrob Agents Chemother. 2015; 59(8):4719-26. PMC: 4505193. DOI: 10.1128/AAC.00835-15. View